Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05736874 · ClinicalTrials.gov registry record · Phase 3
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)
A Phase 3 study, sponsored by Susanna Naggie, MD.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,407
- Enrollment target
NCT05736874: Completed Phase 3 study, sponsored by Susanna Naggie, MD.
NCT05736874 is a Phase 3 study that has completed, run by Susanna Naggie, MD. The registered enrollment target is 1,407 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05736874, a Phase 3 study, has completed, sponsored by Susanna Naggie, MD.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,407 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person. Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the activation of any new drug arms. This protocol was originally registered under NCT04885530. Per recent guidance on reporting master protocol research programs (MPRPs), a separate record for Arm C was created.
Primary Outcome
Time to sustained recovery was the number of days between receipt of study drug and the third of 3 consecutive days without symptoms. Participants who died, by definition, did not recover regardless of reported symptom freedom. The reported summary is the median survival time.
Interventions
- OTHER Placebo
- DRUG Fluticasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,407 participants |
| Start Date | 2021-08-06 |
| Est. Completion | 2022-05-18 |
| Phase | Phase 3 |
What the finished NCT05736874 record still lists
NCT05736874 is an interventional study that assigns participants to a tested intervention. Its 1,407 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05736874 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05736874 about?
NCT05736874 is a clinical study titled "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)". The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or med...
What is the current status of trial NCT05736874?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,407 participants. The study started on 2021-08-06. Estimated completion is 2022-05-18.
What interventions are being tested in trial NCT05736874?
The interventions under investigation include: Placebo (OTHER), Fluticasone (DRUG).
Who is sponsoring clinical trial NCT05736874?
This trial is sponsored by Susanna Naggie, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05736874's enrollment target sits among peer trials
1,407 171st of 2000 higher than 1,829 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT07222566 · 1,410 participants · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI